Rubicon Organics (ROMJ) Q3 2024 earnings summary

Executive summary

• Achieved record net revenue of $13.5 million in Q3 2024, up 34–35% year-over-year, and $34.5 million for the first nine months, up 15% year-over-year.

• Delivered highest adjusted positive EBITDA for the quarter, with $2.0 million in Q3 2024 and positive adjusted EBITDA in eight of the last nine quarters.

• Maintained #1 premium licensed producer status in Canada, leading premium market share across flower, pre-rolls, edibles, and topicals.

• Expanded product portfolio with successful launches in vapes and edibles, with vapes achieving up to 55% national distribution in six months.

• Focused on premium and super-premium cannabis segments, leveraging proprietary cultivation and genetics.

Financial highlights

• Q3 2024 net revenue: $13.5 million; nine-month net revenue: $34.5 million; Q3 gross profit: $4.4 million; gross margin: 32–32.4%.

• Adjusted EBITDA: $2.0 million for Q3 2024; positive for eight of last nine quarters.

• Operating cash flow: $0.9 million in Q3 2024; $1.1 million year-to-date; $5.1 million for 12 months to Q4 2023.

• Cash and cash equivalents: $9.8 million as of September 30, 2024; working capital: $9.6 million.

• Included $0.6 million in one-time ERP implementation costs in Adjusted EBITDA for the nine months.

Outlook and guidance

• Expects continued net revenue growth and increased Adjusted EBITDA for 2024, excluding ERP investment.

• Anticipates vapes to contribute over 20% growth on 2023 net revenue by 2025.

• Plans to secure an additional 20% flower capacity in 2025 and enter new international markets.

• Preparing for international market entry in 2025, targeting premium flower demand.

• Expects to refinance long-term debt before year-end at similar interest rates.